Café

© 2026 Longbridge｜Terms of Service Privacy Policy

AKESO

09926

101.20011.45% ( +10.400 )

Delay Closed: Sep 4, 16:08:03

OverviewOverview NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

Akeso, Summit cancer drug confirms lung cancer survival benefit
biopharmadive·5 hours ago
SMMT+2.77%09926+11.45%
Hong Kong Stock Connect Top 10 Active Names Include MiniMax, Tencent, SMIC
CoinLive·11 hours ago
MNSO-1.14%TCTZF-0.59%
Top 10 HK Stock Gainers (9.4)
Top Gainers&Losers·13 hours ago
07688+15.85%06682+14.66%
UBS: Most China Biotech Firms' 1H26 Sales Beat Expectations; Global R&D Catalysts Key in 2H26, BeOne Medicines Preferred
AASTOCKS News·15 hours ago
01877+0.61%01801-0.19%
Akeso surges 9% as ivonescimab trial hits overall survival endpoint
HK Stock Market Update·16 hours ago
09926+11.45%
CICC Cuts AKESO TP to HKD120, Focuses on Harmoni-2 and Harmoni-3 Data
AASTOCKS News·17 hours ago
09926+11.45%
Daiwa Slightly Raises Confidence in Success of Global First-line NSCLC Phase III Trial OS After AKESO HARMONi-2 Interim OS Analysis Meets Target
AASTOCKS News·18 hours ago
09926+11.45%
Akeso surges 10% as HARMONi-2 trial meets survival endpoint
HK Stock Market Update·18 hours ago
09926+11.45%
STOCKS | Kuaishou, Xiaomi, JD.com And Akeso Rise In Hong Kong Trading
CoinLive·19 hours ago
JD+1.87%KJD+3.98%
Akeso surged 9% on positive Phase III lung cancer data from partner
HK Stock Market Update·20 hours ago
09926+11.45%
Summit Therapeutics Stock (SMMT) Rallies on Positive Clinical Trial Results
Tip Ranks·1 day ago, 03:48 PM
SMMT+2.77%09926+11.45%
Summit Therapeutics strengthened by positive ivonescimab survival results
Tip Ranks·1 day ago, 01:49 PM
SMMT+2.77%09926+11.45%
Akeso, Inc. (9926) Gets a Buy from UBS
Tip Ranks·1 day ago, 01:45 PM
09926+11.45%